+

WO2005011711A3 - Medicament gazeux inhalable a base de xenon et de protoxyde d’azote - Google Patents

Medicament gazeux inhalable a base de xenon et de protoxyde d’azote Download PDF

Info

Publication number
WO2005011711A3
WO2005011711A3 PCT/FR2004/050352 FR2004050352W WO2005011711A3 WO 2005011711 A3 WO2005011711 A3 WO 2005011711A3 FR 2004050352 W FR2004050352 W FR 2004050352W WO 2005011711 A3 WO2005011711 A3 WO 2005011711A3
Authority
WO
WIPO (PCT)
Prior art keywords
xenon
nitrous oxide
medicine based
proportion
volume
Prior art date
Application number
PCT/FR2004/050352
Other languages
English (en)
Other versions
WO2005011711A2 (fr
Inventor
Jacques Abraini
Marc Lemaire
Original Assignee
Air Liquide Sante Int
Jacques Abraini
Marc Lemaire
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Air Liquide Sante Int, Jacques Abraini, Marc Lemaire filed Critical Air Liquide Sante Int
Priority to CA002533499A priority Critical patent/CA2533499A1/fr
Priority to EP04767913A priority patent/EP1651243A2/fr
Priority to JP2006521634A priority patent/JP2007500174A/ja
Priority to US10/563,278 priority patent/US20070053992A1/en
Priority to CN2004800215351A priority patent/CN1829522B/zh
Priority to AU2004260859A priority patent/AU2004260859B2/en
Publication of WO2005011711A2 publication Critical patent/WO2005011711A2/fr
Publication of WO2005011711A3 publication Critical patent/WO2005011711A3/fr
Priority to US12/417,087 priority patent/US20090252816A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur une utilisation d'un mélange gazeux contenant du xénon gazeux et du protoxyde d'azote gazeux, et avantageusement de l'oxygène, pour fabriquer tout ou partie d'un médicament inhalable destiné à prévenir ou à traiter une neuro-intoxication chez l'homme. Le mélange xénon/protoxyde d'azote de l'invention agit sur un ou des récepteurs cérébraux de manière à diminuer la libération et/ou les effets de dopamine, glutamate, serotonine, taurine, GABA, noradrénaline et/ou de tout autre neurotransmetteur. La proportion volumique de xénon du mélange est comprise entre 5 et 45%, et la proportion volumique de protoxyde d'azote est comprise entre 10 et 50%, de préférence le reste est de l'oxygène.
PCT/FR2004/050352 2003-07-30 2004-07-23 Medicament gazeux inhalable a base de xenon et de protoxyde d’azote WO2005011711A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002533499A CA2533499A1 (fr) 2003-07-30 2004-07-23 Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
EP04767913A EP1651243A2 (fr) 2003-07-30 2004-07-23 Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
JP2006521634A JP2007500174A (ja) 2003-07-30 2004-07-23 キセノンと亜酸化窒素に基づく吸入可能なガス状医薬
US10/563,278 US20070053992A1 (en) 2003-07-30 2004-07-23 Inhalable gaseous medicament based on xenon and nitrous oxide
CN2004800215351A CN1829522B (zh) 2003-07-30 2004-07-23 基于氙和一氧化二氮的可吸入性气体药物
AU2004260859A AU2004260859B2 (en) 2003-07-30 2004-07-23 Inhalable gaseous medicament based on xenon and nitrous oxide
US12/417,087 US20090252816A1 (en) 2003-07-30 2009-04-02 Inhalable Gaseous Medicament Based On Xenon And Nitrous Oxide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0350383A FR2858233B1 (fr) 2003-07-30 2003-07-30 Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
FR03/50383 2003-07-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/417,087 Division US20090252816A1 (en) 2003-07-30 2009-04-02 Inhalable Gaseous Medicament Based On Xenon And Nitrous Oxide

Publications (2)

Publication Number Publication Date
WO2005011711A2 WO2005011711A2 (fr) 2005-02-10
WO2005011711A3 true WO2005011711A3 (fr) 2005-05-06

Family

ID=34043809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/050352 WO2005011711A2 (fr) 2003-07-30 2004-07-23 Medicament gazeux inhalable a base de xenon et de protoxyde d’azote

Country Status (8)

Country Link
US (2) US20070053992A1 (fr)
EP (1) EP1651243A2 (fr)
JP (1) JP2007500174A (fr)
CN (1) CN1829522B (fr)
AU (1) AU2004260859B2 (fr)
CA (1) CA2533499A1 (fr)
FR (1) FR2858233B1 (fr)
WO (1) WO2005011711A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2858233B1 (fr) * 2003-07-30 2008-04-11 Air Liquide Sante Int Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
FR2863169B1 (fr) * 2003-12-08 2006-02-10 Air Liquide Sante Int Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications
FR2914633A1 (fr) * 2007-04-06 2008-10-10 Air Liquide Melange gazeux a base d'oxygene et de xenon destine a prevenir ou a diminuer une hyperalgesie
FR2914632B1 (fr) * 2007-04-06 2009-12-18 Air Liquide Melange gazeux a base de o2 de n2o destine a prevenir ou a diminuer l'hyperalgesie
US8425428B2 (en) * 2008-03-31 2013-04-23 Covidien Lp Nitric oxide measurements in patients using flowfeedback
FR2929513B1 (fr) * 2008-04-02 2010-09-17 Air Liquide Traitement des migraines sans aura chez le femmes enceintes par inhalation de dioxygene gazeux.
WO2010035074A1 (fr) * 2008-09-25 2010-04-01 Nnoxe Pharmaceutiques Inc Utilisation d'oxyde de diazote, d'argon, de xénon, d'hélium ou de néon pour fabriquer une composition pharmaceutique destinée à traiter des lésions ischémiques chez des patients ne pouvant pas être traités par des agents thrombolytiques
US8652064B2 (en) * 2008-09-30 2014-02-18 Covidien Lp Sampling circuit for measuring analytes
FR2952305B1 (fr) 2009-11-10 2012-04-27 Air Liquide Medicament inhalable a base de xenon pour traiter ou pour prevenir les dyskinesies
FR2956323B1 (fr) 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
GB2478356A (en) * 2010-03-05 2011-09-07 Esaturnus Nv Nitrous oxide gas for use in preventing adhesion
FR2960778B1 (fr) * 2010-06-03 2012-07-13 Air Liquide Medicament inhalable a base de xenon pour prevenir les rechutes addictives
FR2960779A1 (fr) 2010-06-08 2011-12-09 Air Liquide Medicament gazeux inhalable a base de krypton contre les deficiences ou defaillances d'organes peripheriques
FR2996458B1 (fr) 2012-10-09 2015-02-27 Air Liquide Utilisation de xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique
FR2996457B1 (fr) 2012-10-09 2019-11-29 L'air Liquide,Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Utilisation d'argon pour prevenir ou traiter les consequences neurologiques d'un choc septique
FR2996459B1 (fr) 2012-10-09 2015-02-06 Air Liquide Utilisation d'un melange argon/xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique
EP2931291B1 (fr) * 2012-12-11 2021-10-20 The McLean Hospital Corporation Traitement de xénon comme complément de psychothérapie pour troubles psychiatriques
CN104337830A (zh) * 2013-11-12 2015-02-11 余建强 一种无成瘾性吸入脱毒剂
FR3022456B1 (fr) * 2014-06-20 2016-07-15 Air Liquide Xenon associe a un antagoniste des recepteurs nmda pour lutter contre une proliferation tumorale dans le systeme nerveux central
FR3027226B1 (fr) * 2014-10-17 2017-12-08 L'air Liquide Sa Pour L'etude Et L'exploitation Des Procedes Georges Claude Medicament pour traiter une maladie liee a un dysfonctionnement de la transmission synaptique dopaminergique
CN104688767B (zh) * 2015-03-17 2017-10-24 宁夏恩多芬科技有限公司 安桃乐在制备用于戒毒药物中的用途
CN108066355A (zh) * 2017-12-28 2018-05-25 宁夏恩多芬科技有限公司 Nitrous Oxide作为治疗神经官能症的用途
RU2758536C1 (ru) * 2020-12-17 2021-10-29 Федеральное Государственное Бюджетное Научное Учреждение "Федеральный Научно-Клинический Центр Реаниматологии И Реабилитологии" (Фнкц Рр) Способ снижения воспалительной гиперактивации нейтрофилов

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2596989A1 (fr) * 1986-04-14 1987-10-16 Air Liquide Produit de radiosensibilisation des tissus biologiques en radiotherapie
EP0861672A1 (fr) * 1995-09-20 1998-09-02 Panina, Elena Vladimirovna Procede de production d'un melange respiratoire gazeux et appareil de mise en oeuvre de ce procede
WO2000053192A1 (fr) * 1999-03-11 2000-09-14 Aga Ab Utilisation de xenon pour traiter les neurointoxications
US6274633B1 (en) * 1999-07-29 2001-08-14 Imperial College Of Science, Technology, And Medicine NMDA antagonist

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1179997A1 (ru) * 1973-02-28 1985-09-23 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латсср Средство дл лечени паркинсонизма "глудантан
US3876773A (en) * 1973-05-15 1975-04-08 British Oxygen Co Ltd Gas mixtures containing nitrous oxide
US5846556A (en) * 1996-06-14 1998-12-08 Brooks; Bradley S. Inhalant for reducing stress and method of use
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
FR2858233B1 (fr) * 2003-07-30 2008-04-11 Air Liquide Sante Int Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
FR2863169B1 (fr) * 2003-12-08 2006-02-10 Air Liquide Sante Int Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2596989A1 (fr) * 1986-04-14 1987-10-16 Air Liquide Produit de radiosensibilisation des tissus biologiques en radiotherapie
EP0861672A1 (fr) * 1995-09-20 1998-09-02 Panina, Elena Vladimirovna Procede de production d'un melange respiratoire gazeux et appareil de mise en oeuvre de ce procede
WO2000053192A1 (fr) * 1999-03-11 2000-09-14 Aga Ab Utilisation de xenon pour traiter les neurointoxications
US6274633B1 (en) * 1999-07-29 2001-08-14 Imperial College Of Science, Technology, And Medicine NMDA antagonist

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVID H N ET AL: "REDUCTION OF ISCHEMIC BRAIN DAMAGE BY NITROUS OXIDE AND XENON", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, RAVEN PRESS, LTD., NEW YORK, NY, US, vol. 23, no. 10, 1 October 2003 (2003-10-01), pages 1168 - 1173, XP008027594, ISSN: 0271-678X *
LICHTIGFELD F J ET AL: "Psychotropic analgesic nitrous oxide and neurotransmitter mechanisms involved in the alcohol withdrawal state.", THE INTERNATIONAL JOURNAL OF NEUROSCIENCE. ENGLAND MAY 1994, vol. 76, no. 1-2, May 1994 (1994-05-01), pages 17 - 33, XP008028205, ISSN: 0020-7454 *

Also Published As

Publication number Publication date
CN1829522A (zh) 2006-09-06
JP2007500174A (ja) 2007-01-11
WO2005011711A2 (fr) 2005-02-10
AU2004260859A1 (en) 2005-02-10
EP1651243A2 (fr) 2006-05-03
US20090252816A1 (en) 2009-10-08
AU2004260859B2 (en) 2009-12-24
FR2858233B1 (fr) 2008-04-11
US20070053992A1 (en) 2007-03-08
FR2858233A1 (fr) 2005-02-04
CA2533499A1 (fr) 2005-02-10
CN1829522B (zh) 2010-05-12

Similar Documents

Publication Publication Date Title
WO2005011711A3 (fr) Medicament gazeux inhalable a base de xenon et de protoxyde d’azote
WO2008012531A3 (fr) Administration de gaz dans les voies nasales
WO2007008619A3 (fr) Systeme de regulateur de gaz supplementaire modulaire et systeme de traitement respiratoire dans lequel est utilise ce systeme de regulateur
DE60330437D1 (de) Luftfluss
WO2007063532A3 (fr) Cire d'occlusion endoscopique
AU2003283398A1 (en) Use of trans-pellitorin in the form of an aromatic substance
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
EG24236A (en) Respirators
DK2014293T3 (da) Anvendelse af argon i gasformig tilstand til at behandle neurointoxikation
WO2005041864A3 (fr) Technique de traitement de prevention d'inflammation respiratoire avec un inhibiteur de cyclooxygenase-2 combine a un inhibiteur de phosphodiesterase 4 et compositions a partir de ceux-ci
AU2003258613A1 (en) Device for influencing gas flows
WO2006086006A3 (fr) Bouteille d'eau et d'oxygene
WO2005077005A3 (fr) Amelioration de l'efficacite d'un gaz therapeutique inhale
IL168308A (en) Compositions containing roflumilast and formoterol
WO2005110052A3 (fr) Utilisation d'oxyde nitrique gazeux inhale en tant qu'agent mucolytique ou expectorant
WO2002069944A3 (fr) Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de recepteurs nk1
US7204246B1 (en) Air self-contained oxygen inhaler
AU2001297652A1 (en) Method for treating respiratory distress syndrome
DK1438963T3 (da) Anvendelse af N2O til behandling af post-iskærmiske forringelser af hjerneceller
BR112012010898A8 (pt) Dispositivo de distribuição de aroma portátil de mão
EP1260221A3 (fr) Therapie de combinaison de la depression et de l'anxieté
RU2002125528A (ru) Дыхательный аппарат
MD2327G2 (ro) Metodă de tratament al afecţiunilor parodonţiului
WO2003033014A3 (fr) Nouvelle utilisation de surfactant pulmonaire
RU2004117835A (ru) Способ повышения работоспособности человека

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480021535.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004767913

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2533499

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006521634

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004260859

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004260859

Country of ref document: AU

Date of ref document: 20040723

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004767913

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007053992

Country of ref document: US

Ref document number: 10563278

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10563278

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载